Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients

NCT04152629 is registered in ClinicalTrials.gov with Purdue Pharma, Canada as lead sponsor.

NCT NCT04152629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients
Lead sponsor
Purdue Pharma, Canada
Phase
Phase 4
Overall status
Completed
Start date
September 19, 2019
Completion date
July 9, 2021
Enrollment
257 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit-hyperactivity disorder